respiratory syncytial virus

The seven newly appointed members of ACIP voted 5-to-2 to recommend Enflonsia, the second long-acting monoclonal ...

JUNE 26, 2025

The FDA has approved the second monoclonal antibody for the prevention of RSV in neonates and infants, ...

JUNE 10, 2025

Sanofi said it would ship nirsevimab starting earlier to ensure broad availability well ahead of the 2025-2026 RSV ...

JUNE 9, 2025

The FDA required and approved safety labeling changes to the prescribing information for RSV vaccines to include a ...

JANUARY 14, 2025

As the respiratory season heats up, two recent reports from the CDC detail how vaccination for influenza, RSV and ...

JANUARY 6, 2025

The FDA approved mRESVIA, the first mRNA RSV vaccine to protect adults, 60 years of age and older, from LRTD caused ...

MAY 31, 2024

Potentially dangerous administration errors for RSV vaccines are occurring in young children and pregnant people, ...

APRIL 21, 2024

The severity of the 2023-2024 respiratory virus season was generally moderate, and while a tripledemic consisting ...

APRIL 9, 2024

Confusion over similar product names with different indications likely are the cause of administration errors of ...

MARCH 1, 2024

RSV is a prevalent pathogen that presents as a minor common cold in most individuals, but poses a higher risk to ...

FEBRUARY 13, 2024

The CDC announced 77,000 additional doses of nirsevimab-alip, a long-acting monoclonal antibody designed to protect ...

NOVEMBER 17, 2023

The CDC recommended the first respiratory syncytial virus vaccine given during pregnancy to protect the newborn ...

SEPTEMBER 26, 2023